ORIGINAL ARTICLE

Germ-line sequence variants of *PTEN* do not have an important role in hereditary and non-hereditary prostate cancer susceptibility

Chunmei C Xie^{1,2}, Lingyi Lu^{1,3}, Jieli Sun^{1,4}, S Lilly Zheng^{1,4}, William B Isaacs⁵, Henrik Gronberg⁶ and Jianfeng Xu^{1,4}

PTEN (phosphatase and tensin homolog deleted on chromosome 10) functions as a major tumor suppressor gene and is frequently deleted in different types of tumors including prostate cancer (PCa). It was hypothesized that germ-line genetic changes of *PTEN* affect susceptibility to PCa. Both common (with a minor allele frequency $\geq 5\%$) and rare (with a minor allele frequency $< 5\%$) germ-line variants of *PTEN* were comprehensively evaluated. A total of 15 germ-line variants were identified by re-sequencing the *PTEN* gene, including 5' untranslated region, all nine exons, exon-intron junctions and 3' untranslated region, in 188 probands of hereditary prostate cancer (HPC) families recruited from Johns Hopkins Hospital. Two microsatellite markers surrounding *PTEN* were used to test the co-segregation of 10 rare variants, which may give rise to highly penetrance in HPC. Two common single nucleotide polymorphisms (SNPs) were evaluated in the 188 HPC families using a family-based association study approach. To study low penetrant SNPs in PCa susceptibility, 33 SNPs covering *PTEN* were selected from the whole genome-wide association studies (GWAS) from our available case-control studies in Sweden (Cancer of the Prostate in Sweden (CAPS)) and the publicly available cancer genetic markers of susceptibility (CGEMS) study. Germ-line copy-number variations (CNVs) in *PTEN* were assessed in CAPS. Co-segregation of germ-line variants and PCa was not observed among HPC families and no significant differences in the allele frequencies were observed in sporadic cases and controls, aggressive and non-aggressive PCa ($P > 0.05$). These results suggest that germ-line variants in *PTEN* do not have an important role in PCa susceptibility.

Journal of Human Genetics (2011) 56, 496–502; doi:10.1038/jhg.2011.48; published online 2 June 2011

Keywords: co-segregation; family-based association; population-based association; prostate cancer; *PTEN*; sequencing

INTRODUCTION

Located on chromosome 10q23, *PTEN* is frequently deleted in multiple tumors including prostate cancer (PCa). *PTEN* has been shown to be involved in many cellular functions including apoptosis, cell-cycle control, cell adhesion and migration; however, the primary function of *PTEN* is to dephosphorylate and inactivate the second messenger PIP3.¹ It exerts its tumor suppressor function by acting as a negative regulator in the PI3K signaling pathway.¹ Loss of *PTEN* has been shown to contribute to PCa development in mouse models,^{2–5} and mutations or deletions of *PTEN* have been found to occur frequently in PCa in human, especially in advanced disease.^{6–10}

Deleterious germ-line variants in *PTEN* were not found to contribute to PCa susceptibility in previous studies, including muta-

tion screening, linkage studies and genome-wide association (GWA) studies in case-control sporadic PCa populations.^{11–16} Some limitations of these studies were small sample size, low-coverage of the *PTEN* gene for mutation screening and the lack of evaluation of co-segregation of *PTEN* germ-line variants and PCa risk. In this report, a comprehensive assessment of germ-line variants in the *PTEN* gene for PCa susceptibility was carried out, which included mutation screening of a sizeable *PTEN* region in a large hereditary prostate cancer (HPC) sample, co-segregation analysis of high penetrant variants (rare variants with a minor allele frequency $\geq 5\%$) in HPC families, association analysis of low penetrant variants (common single nucleotide polymorphisms (SNPs) with a minor allele frequency $< 5\%$) in sporadic PCa and evaluation of copy-number variations (CNVs) in *PTEN* in sporadic PCa populations.

¹Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA; ²Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; ³Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA; ⁴Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC, USA; ⁵Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA and ⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Correspondence: Dr J Xu, Center for Cancer Genomics, Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

E-mail: jxu@wfbmc.edu

Received 15 December 2010; revised 7 April 2011; accepted 14 April 2011; published online 2 June 2011

MATERIALS AND METHODS

Subjects

Hereditary prostate cancer (HPC) families. A detailed description of the HPC study families has been presented in previous work.¹⁷ In total, 188 HPC families with at least three first-degree relatives having a diagnosis of PCA were recruited into the study by investigators at the Brady Urology Institute at Johns Hopkins Hospital (JHH, Baltimore, MD, USA). The mean age at diagnosis for these individuals was 64.3 years. Approximately 91.8% of the families were Caucasian and 9.2% were Black. The average number of affected individuals per family was 5.08. The number of families with 3, 4 and 5 or more affected individuals was 28, 47 and 113, respectively. Proband was selected based on the following priorities: affected member with metastatic disease, local invasion, highest Gleason score, highest preoperative prostate-specific antigen (PSA) levels and youngest age at diagnosis.

JHH case-control population. The 1527 cases were from a consecutive series of men who underwent treatment for PCA at JHH. Diagnosis of PCA of the cases was confirmed by pathology reports. Paraffin-embedded tissue and frozen tissue were available for 95% and 35% of cases, respectively. The mean age, PSA, Gleason Score and stage for the cases were 58.5 years, 7.9 ng ml⁻¹, 6.8 and 1.5, respectively. The 482 unaffected controls were recruited from a series of consecutive men that participated in PCA screenings at the Brady Urological Institute at JHH. Mean age and PSA for the controls were 57.5 years and 1.6 ng ml⁻¹. DNA from blood samples was available for all cases and controls.

Cancer of the prostate in Sweden (CAPS) population. The population-based, case-control study in Sweden, named Cancer Prostate in Sweden (CAPS) was used to complete fine-mapping in the study.¹⁸ Cases with pathologically

diagnosed PCA were recruited from regional cancer registries in Sweden, between July 2001 and October 2003. DNA from blood samples, tumor-node metastasis stage, Gleason grade (biopsy) and PSA levels were available for 2899 cases. Controls were recruited concurrently from the Swedish Population Registry and matched with cases according to age and geographic region. DNA from blood samples was available for 1722 controls. Subsets of the CAPS population were used for two genome-wide association study (GWAS) studies: GASP1 and GASP2. GASP1 included 500 cases and 500 controls and GASP2 included 1500 cases and 500 controls.

Cancer genetic markers of susceptibility (CGEMS) population. The published data from the National Cancer Institute (CGEMS) study was also used.^{19,20} The study population was the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial and it included 1177 cases and 1105 controls.

Sequencing and genotyping of SNP and microsatellite markers

The entire genomic sequence of *PTEN* was re-sequenced, including the ~2 kb region of the promoter, all coding regions, the 3' and 5' untranslated regions, and regions that were evolutionarily conserved from multiple species comparison in probands ($n=188$) of the HPC families. Figure 1 outlines the gene organization of *PTEN* and Table 1 lists the primers used to amplify the PCR products, the sizes of amplified PCR fragments and the annealing temperature for each pair of primers. All reactions were performed using Taq polymerase (Invitrogen, Carlsbad, CA, USA) at a 10-μl scale consisting of 20 ng genomic DNA, 0.2 μmol l⁻¹ of each primer, 0.2 mmol l⁻¹ of each deoxynucleotide triphosphate, 1.5 mmol l⁻¹ MgCl₂, 20 mmol l⁻¹ Tris-HCl, 50 mmol l⁻¹ KCl and 0.5 units Taq polymerase (Invitrogen). PCR cycling conditions were as follows: 94 °C for 3 min followed by 33 cycles of 94 °C for 30 s, a specified annealing temperature for 30 s, and 72 °C for 30 s, with a final extension of 72 °C for 6 min. The PCR products were purified using the QuickStep PCR Purification kit (Edge BioSystems, Gaithersburg, MD, USA) to remove deoxynucleotide triphosphates and excess primers. All sequencing reactions were carried out using dye terminator chemistry (BigDye, ABI, Foster City, CA, USA) and then precipitated using 75 ± 5% ethanol. Samples were loaded onto an ABI 3700 DNA analyzer after adding 8 μl formamide. SNPs were identified using Sequencer software version 4.0.5 (Gene Codes, Ann Arbor, MI, USA).

Genotyping for the two common SNPs (rs12573787 and rs1903858) was carried out using the MassARRAY system (Sequenom, San Diego, CA, USA) in the 188 HPC families for which DNA samples were available. The SNP rs1903858 was selected to be genotyped in an additional 1527 sporadic PCA cases and 482 unaffected controls from the JHH case-control population. PCR and extension reactions were carried out according to the manufacturer's instructions and extension product sizes were determined by mass spectrometry.

The microsatellite markers D10S1686 and D10S185, which lie on either side of the *PTEN* gene in the region of 100.5~102.5 cM and span an interval of

Figure 1 *PTEN* gene structure with sequence variants indicated (map distance in kb); 15 sequence variants were found. Physical location: 89 613 715–89 718 382 bp, NCBI Build 35.

Table 1 Primers used for mutational analysis and SNPs identification in *PTEN* (89 613 715–89 718 382 bp), NCBI Build 35

PCR ID	Forward primer (5'-3')	Reverse primer (5'-3')	PCR product (bp)	Annealing temperature
1	AAGGGGAATCTCTAGGCAA	AGCATGCCAGTGTAGCTG	453	62
2	AGCAAGTGCAGCTGCAGG	AGAGGCTGCACGGTTAGAAA	579	62
3	CTCTCAGCGCCTGTGAGC	GGACTTGGCGGTAGCTGAT	638	62
4	CCAGTCGCTGCAACCATC	TGCAACCAGGCAAGAGTTC	473	68
5	CTGTCCATGTGGAAGTTACCTT	CTGTATCCCCTGAAGTCCA	460	62
6	CCATAGAAGGGGTATTTGTTGG	CATGAATCTGTGCCAACATG	420	58
7	AAAGATTCAGGCAATGTTTGT	ATGCTGCACTTAGTCTTCCTG	350	60
8	TTTCTCTGGAATCCAGTGTTC	CAGATCCAGGAAGAGGAAAGG	413	60
9	GCTACGACCCAGTTACCATAGC	CCAATGAGTTGAACAACAAAGC	404	60
10	TTGCTTGAGATCAAGATTGCA	CTCACCAGTGCAGAGTAAGC	446	60
11	TTTTGTTGACTTTTGTCAATG	GTCAAGCAAGTCTTTCATCAGC	442	62
12	AAGAGGGTCATTTAAAGGCC	TCTGACACAATGTCTATTGCC	453	60
13	CCAGAGAATGAACCTTTTGATG	ACCCTTCGAAACCTCTCTTAG	520	68
14	GTTCTGTCCAACTGAAGTGG	AGCATCCACAGCAGGTATTATG	679	63

~9.6 Mb, were genotyped in HPC families with rare sequence variants to estimate the co-segregation of sequence variants with PCa in HPC families. The genotyping method has been previously described in detail.²¹

SNPs in the *PTEN* gene selected from genome-wide association study (GWAS)

To study low penetrant SNPs in PCa susceptibility, 33 SNPs within the *PTEN* gene were selected from the GWAS of GASP1, GASP2 and CGEMS (see Figure 2). Data from the three existing GWAS studies, which were deposited from Hapmap (<http://www.hapmap.org>, rel#21, dbSNPb125) was used to test the 33 SNPs spanning the complete *PTEN* gene (105.3 kb), GeneChip Human Mapping 500k Array, 5.0 Array (Affymetrix, Santa Clara, CA, USA) and HumanHap 300 BeadChips (Illumina, San Diego, CA, USA) were used for GASP1, GASP2 and CGEMS.^{19,22} The detection of SNPs and CNVs in the CAPS population by means of Affymetrix SNP has been previously described in detail.^{22,23} Results for a subset of the 33 SNPs spanning *PTEN* were obtained from the GWAS (results from GASP1, GASP2 and CGEMS) and were used for the imputation of the remaining SNPs.

Statistical methods

Family-based association tests (FBAT) were performed for two SNPs (rs12573787 and rs1903858) in HPC families including 1286 affected and unaffected members, using the software package FBAT.²⁴ Linkage and linkage disequilibrium between PCa and SNPs were assessed by FBAT based on the data from nuclear families, sibships or a combination of the two.

Parametric and non-parametric analyses were carried out to test the co-segregation of the sequence variants in the HPC families using GeneHunter Plus (<http://www.broad.mit.edu/ftp/distribution/software/genehunter/>). In the

parametric analysis, the frequency of the susceptibility allele was assumed to be 0.003, and penetrance for non-carriers and carriers was 0.001 and 1.0, respectively. In the recessive model, the frequency of the susceptibility allele was set to be 0.15, and the penetrances for heterozygous carriers and homozygous carriers were assumed to be equal.

Linkage heterogeneity among families (HLOD) was estimated using HOMOG (Ott 1999). In non-parametric analysis, LOD scores were calculated using the Kong and Cox exponential allele sharing model score (KCLOD). Multipoint linkage statistics were performed at 0.5-cM intervals across the region covering *PTEN* gene.

To test associations between the SNPs and CNVs and PCa, allele frequencies between cases and controls for each SNP were compared. LD structure was formed by Haploview (<http://www.broadinstitute.org/mpg/haploview>). The differences in allele frequencies between cases and controls were tested using standard contingency χ^2 tests, and *P*-values were determined via χ^2 approximation. All of the known SNPs in *PTEN* were imputed based on the genotyped SNP information in the HapMap Phase II data (CEU) using a computer program, IMPUTE.²⁵ Odds ratio and 95% confidence interval were estimated using an unconditional logistic regression with adjustment for age and geographic region, assuming an additive model of inheritance.

RESULTS

SNP identification

A total of 15 genetic variants were identified in the sequenced region of *PTEN* in the 188 HPC probands. Five of the variants had already been previously reported (rs1044322, rs12573787, rs1903858, rs34051577 and rs1044487) and none of the 15 was located in exons (http://www.ncbi.nlm.nih.gov/SNP/snp_ref). The location and

Figure 2 33 SNPs spanning *PTEN* (89 623 195–89 728 531 bp, NCBI build 37); Color scheme is based on standard *D'*/LOD score option in Haploview 4.1.

Table 2 Sequence variants of PTEN identified in 188 HPC probands

Variant ID (position) ^a	Sequence variants	Position	Frequency
1 (-1287)	SNP-1287C/G	Promoter	CG: 1.2%; CC: 98.8%; GG: 0
2 (-1060)	SNP-1060C/G	5'UTR	CG: 0.7%; CC:99.3%; GG:0
3 (-976)	SNP-976G/C	5'UTR	GC:0.7%; GG:99.3%; CC:0
4 (-904)	SNP-904G/A	5'UTR	GA: 3.4%; GG:96.6%; AA:0
5 (-546)	INDEL-546 5GGC/6GGC	5'UTR	5/6:2.6%; 5/5:97.4%; 6/6:0
6 rs12573787 (-511)	SNP-511G/A	5'UTR	GA:22%; GG:77%; AA:0.7%
7 (-500)	INDEL-500 5GGC/6GGC/7GGC	5'UTR	5/6:0.7%; 5/7:0.7%; 5/5:98.6%; 6/6:0; 7/7:0
8 (-461)	SNP-461G/A	5'UTR	GA:0.7%; GG:99.3%; AA:0
9 (210)	SNP 210T/C	Intron 1	TC:0.6%; TT:99.4%; CC:0
10 rs1903858 (29460)	SNP 29460C/T	Intron 1	CT:47.3%; TT:43.2%; CC:9.5%
11 (66729)	INDEL 66729 TCTTA/_	Intron 4	TCTTA/-:44%; _/:45.6%; TCTTA/TCTTA:10.6%
12 (68506)	INDEL 68506 9T/10T	Intron 4	9/10:1.8%; 9/9:98.2%; 10/10:0
13 (93573)	SNP 93573G/A	Intron 7	GA:1.8%; GG:98.2%; AA:0
14 (96422)	INDEL 96422 15T/14T	Intron 7	15/14:100%; 15/15:0; 14/14:0
15 (101068)	INDEL 101068 11T/10T	3'UTR	11/10:100%; 11/11:0; 10/10:0

Abbreviations: HPC, hereditary prostate cancer; INDEL, insertion/deletion; SNP, single nucleotide polymorphism; UTR, untranslated region.
^aPosition is relative to ATG translation start.

frequency of each variant are presented in Figure 1 and Table 2. Of the 15 sequence variants, 5 are common variants with a minor allele frequency $\geq 5\%$ and 10 are rare variants with a minor allele frequency $< 5\%$. Of the five common variants, two are SNPs and the three are insertion/deletions.

Co-segregation of rare SNPs and PCa in HPC families

LOD scores for two markers (D10S1686 and D10S185) flanking *PTEN* located in the region of 100.5~102.5 cM are shown in Table 3. HLOD scores were used to present the LOD score for the family group of each SNP. Both dominant and recessive parametric analyses were carried out, and evidence of co-segregation of rare SNPs in the HPC families was not observed. Non-parametric analysis was also carried out and co-segregation of the rare SNPs and PCa was not found (data not shown).

Family-based association test (FBAT)

Two common SNPs, rs12573787 and rs1903858, which were in the 5' untranslated region and intron 1, were further genotyped in the FBAT. An association between the two variants and PCa was not observed, suggesting the variants were not overtransmitted from parents to affected sons in the 188 HPC families including 1286 affected and unaffected family members (Table 4, $P > 0.05$). Subset analysis of FBAT were also carried out by breaking the families down by the number of affected males (number=3, 4 and ≥ 5) and age at onset (< 65 or > 65). None of these sub groups showed significant association for these two SNPs in FBAT analysis (all $P > 0.05$).

Association test in sporadic PCa cases and controls

The SNP rs1903858 was selected for association analysis among sporadic PCa cases and controls. The frequency of rs1903858 is 0.31 in cases ($n=1527$) and 0.30 in controls ($n=482$) from the JHH population. No significant difference in the allele frequencies was found between sporadic PCa cases and controls ($P=0.592$).

Of the 33 SNPs that spanned the *PTEN* gene that were selected for association testing with sporadic PCa, there were 28 common SNPs ($\geq 5\%$ frequency) identified with an average spacing of one common SNP every ~ 3.7 kb. In the *PTEN* gene, four SNPs were

Table 3 Co-segregation of 10 rare SNPs in *PTEN* in HPC families

Variant ID	Family number	LOD score (HLOD)					
		Dominant			Recessive		
		100.5 cM	101.5 cM	102.5 cM	100.5 cM	101.5 cM	102.5 cM
1	2	0.09	0.11	0.12	0.08	0.07	0.07
2	1	0	0	0	0	0	0
3	1	0	0	0	0	0	0
4	5	0	0	0	0	0	0
5	4	0	0	0	0	0	0
7	2	0.03	0.03	0.03	0.04	0.04	0.03
8	1	0	0	0	0	0	0
9	1	0	0	0	0	0	0
12	3	0	0	0.02	0	0.01	0.02
13	3	0	0	0	0	0	0
All_above_fam	23	0	0	0	0	0	0

Abbreviations: HPC, hereditary prostate cancer; SNP, single nucleotide polymorphism.

Table 4 Results of the FBATs for two common SNPs in *PTEN*

SNPs	Chromosome position	Alleles	Risk allele	Allele frequency	P-values ^a
rs12573787	89 613 696	A/G	A	0.12	0.9
rs1903858	89 643 666	C/T	C	0.7	0.99

Abbreviations: FBATs, family-based association tests; SNP, single nucleotide polymorphism.
^aFBAT test: HPC cases vs controls.

genotyped in GASP1 and GASP2 and eight SNPs were genotyped in CGEMS GWAS studies. The remaining SNPs in *PTEN* were imputed based on the four SNPs genotyped in GASP1 and GASP2 GWAS or eight SNPs genotyped in CGEMS GWAS. None of the 33 SNPs (genotyped or imputed) was found to be significantly associated with PCa susceptibility in any these studies, shown as in Table 5 ($P > 0.05$). The 33 SNPs were also tested for

their association with PCa aggressiveness in CGEMS and GASP2 populations (all cases in GASP1 population are aggressive). None of them was found to be significantly associated with aggressiveness in these two populations, as shown in Table 6 (all $P > 0.05$).

Copy-number variations (CNVs) analysis

In addition to testing the association of germ-line SNPs and PCa susceptibility, germ-line CNVs in *PTEN* and the association with sporadic PCa was also evaluated with three SNP probes (rs12569998, rs11202600 and rs17107001) at *PTEN* region on Gene-Chip Human Mapping 5.0 Array (Affymetrix). The CNV defined by the three probes in *PTEN* was not associated with PCa risk from GWAS in CAPS population (data not shown).

DISCUSSION

In this report, germ-line sequence variants of *PTEN* in both HPC and sporadic prostate cancer were comprehensively evaluated. The *PTEN* gene was screened, including the 5' untranslated region, all nine exons, exon-intron junctions and 3' untranslated regions, in HPC probands.

The co-segregation of *PTEN* mutations/sequence variants in HPC families and association in a sporadic PCa population were also evaluated. To summarize, 10 rare and 5 common variants were identified by sequencing, however, we were unable to identify any potentially important mutations, such as mutations in exons from germ-line DNA samples of 188 HPC probands. There was no statistically significant difference in allele frequencies of the two common SNPs, rs12573787 and rs1903858, between cases and controls after genotyping 1286 HPC members and no statistical difference in the allele frequency of one common SNP after genotyping in 1527 PCa cases and 482 controls. Additionally, there was no evidence of co-segregation of variants in *PTEN* in the HPC families. The 33 SNPs that spanned the *PTEN* gene showed no association between *PTEN* and PCa susceptibility in the CAPS and CGEMS population. None of the 33 SNPs was shown to be associated with aggressiveness of PCa. Finally, in the results of evaluating CNVs in *PTEN* from the available data in CAPS, there were no detectable CNV changes associated with PCa (data not shown). The results suggest that *PTEN* gene variants do not have an effect on PCa susceptibility and aggressiveness.

Table 5 Frequency of 33 SNPs spanning *PTEN* in three GWAS studies

SNP	Position	Minor allele	CGEMS (1177 cases/1105 controls)					GASP1 (500 cases/500 controls)					GASP2 (1500 cases/500 controls)				
			F _A [▲]	F _U [▲]	P ^a	OR ^a	Status	F _A [▲]	F _U [▲]	P ^a	OR ^a	Status	F _A [▲]	F _U [▲]	P ^a	OR ^a	Status
rs3781195	89632589	G	0.03	0.02	0.81	1.05	Imputed	0.03	0.01	0.011	2.29	Imputed	0.02	0.02	0.79	1.07	Imputed
rs1234220	89635453	G	0.10	0.10	0.63	1.05	Original	0.11	0.09	0.19	1.22	Imputed	0.10	0.12	0.17	0.85	Imputed
rs11202596	89637134	A	0.09	0.08	0.70	1.04	Original	0.04	0.04	0.57	0.86	Imputed	0.05	0.05	0.95	0.99	Imputed
rs1234219	89639557	G	0.08	0.07	0.60	1.06	Imputed	0.06	0.06	0.96	1.01	Imputed	0.06	0.08	0.24	0.84	Imputed
rs7069904	89639818	A	0.02	0.02	0.16	1.34	Imputed	0.02	0.01	0.046	2.72	Imputed	0.01	0.00	0.61	1.33	Imputed
rs1234218	89640739	T	0.07	0.07	0.84	1.02	Imputed	0.05	0.06	0.74	0.94	Imputed	0.06	0.07	0.24	0.84	Imputed
rs1903858	89643666	G	0.31	0.28	0.03	1.16	Imputed	0.29	0.30	0.78	0.97	Imputed	0.27	0.28	0.95	0.99	Imputed
rs2299939	89647130	A	0.19	0.19	0.63	1.04	Original	0.08	0.10	0.24	0.79	Imputed	0.09	0.08	0.45	1.14	Imputed
rs1234225	89663549	T	0.35	0.32	0.08	1.12	Imputed	0.34	0.35	0.67	0.96	Imputed	0.33	0.35	0.39	0.93	Imputed
rs12569998	89664137	G	0.14	0.13	0.29	1.10	Imputed	0.14	0.14	0.85	0.98	Original	0.13	0.13	0.71	1.04	Original
rs1234224	89665276	G	0.35	0.32	0.08	1.12	Imputed	0.34	0.35	0.67	0.96	Imputed	0.33	0.35	0.39	0.93	Imputed
rs1234223	89665570	C	0.10	0.10	0.70	1.04	Imputed	0.11	0.09	0.21	1.21	Imputed	0.10	0.12	0.17	0.85	Imputed
rs17106896	89667087	T	0.05	0.04	0.23	1.19	Imputed	0.02	0.01	0.049	2.69	Imputed	0.01	0.00	0.40	1.59	Imputed
rs1676759	89668276	G	0.03	0.02	0.72	1.07	Imputed	0.01	0.01	0.58	1.35	Imputed	0.01	0.00	0.34	1.68	Imputed
rs11202600	89672813	C	0.07	0.07	0.84	1.02	Imputed	0.07	0.07	0.98	1.00	Original	0.08	0.10	0.053	0.79	Original
rs10490920	89675623	C	0.14	0.13	0.29	1.10	Imputed	0.14	0.14	0.82	0.97	Imputed	0.13	0.13	0.75	1.04	Imputed
rs1234213	89679301	A	0.35	0.32	0.07	1.12	Imputed	0.34	0.35	0.66	0.95	Imputed	0.33	0.35	0.39	0.93	Imputed
rs7078674	89687333	T	0.00	0.00	NA	NA	Imputed	0.00	0.00	NA	NA	Imputed	0.00	0.00	NA	NA	Imputed
rs12357281	89690651	C	0.09	0.08	0.75	1.04	Imputed	0.04	0.04	0.65	0.89	Imputed	0.05	0.05	0.88	0.97	Imputed
rs2299941	89694699	G	0.14	0.13	0.23	1.11	Imputed	0.14	0.14	0.99	1.00	Imputed	0.13	0.12	0.87	1.02	Imputed
rs2735343	89695409	C	0.35	0.32	0.09	1.11	Imputed	0.34	0.35	0.65	0.95	Imputed	0.33	0.35	0.37	0.93	Imputed
rs2248293	89697245	C	0.35	0.32	0.07	1.12	Original	0.31	0.31	0.98	1.00	Imputed	0.30	0.33	0.16	0.88	Imputed
rs17562384	89699396	C	0.19	0.19	0.59	1.04	Imputed	0.08	0.10	0.25	0.79	Imputed	0.09	0.08	0.44	1.14	Imputed
rs2673832	89702453	G	0.11	0.11	0.92	0.99	Original	0.01	0.02	0.22	0.56	Imputed	0.02	0.01	0.38	1.35	Imputed
rs12572106	89706087	C	0.14	0.13	0.27	1.10	Imputed	0.14	0.14	0.82	0.97	Imputed	0.13	0.13	0.75	1.04	Imputed
rs17431184	89710231	C	0.19	0.19	0.60	1.04	Imputed	0.08	0.10	0.25	0.79	Imputed	0.09	0.08	0.43	1.15	Imputed
rs2736627	89711074	C	0.09	0.10	0.43	0.92	Imputed	0.01	0.02	0.22	0.56	Imputed	0.02	0.01	0.38	1.35	Imputed
rs926091	89711392	T	0.14	0.13	0.27	1.10	Imputed	0.14	0.14	0.82	0.97	Imputed	0.13	0.13	0.75	1.04	Imputed
rs532678	89713322	T	0.35	0.32	0.08	1.12	Imputed	0.34	0.35	0.65	0.95	Imputed	0.33	0.35	0.37	0.93	Imputed
rs11202607	89717394	T	0.07	0.07	0.99	1.00	Original	0.05	0.06	0.74	0.94	Imputed	0.06	0.07	0.24	0.84	Imputed
rs478839	89721850	G	0.40	0.42	0.41	0.95	Original	0.40	0.38	0.39	1.11	Imputed	0.38	0.37	0.89	1.01	Imputed
rs17346680	89727081	A	0.04	0.03	0.29	1.19	Imputed	0.04	0.02	0.003	2.24	Original	0.07	0.08	0.11	0.80	Original
rs10509532	89727534	T	0.14	0.13	0.26	1.10	Original	0.14	0.14	0.78	0.96	Original	0.13	0.13	0.75	1.04	Original

Abbreviations: CGEMS, cancer genetic markers of susceptibility; GWAS, whole genome-wide association study; OR, odds ratio; SNPs, single nucleotide polymorphisms.

^aP and OR are calculated based on an unconditional logistic regression with adjustment for age and geographic region, assuming an additive model of inheritance. [▲]F_A, frequency in affected cases; F_U, frequency in controls.

Table 6 Frequency of 33 SNPs spanning *PTEN* in 2 GWAS studies

SNP	Position	Minor allele	CGEMS (650 aggressive/527 non-aggressive)					GASP2 (637 aggressive/863 non-aggressive)				
			F_A [▲]	F_U [▲]	P ^a	OR ^a	Status	F_A [▲]	F_U [▲]	P ^a	OR ^a	Status
rs3781195	89632589	G	0.03	0.03	0.82	1.06	Imputed	0.02	0.02	0.84	0.95	Imputed
rs1234220	89635453	G	0.11	0.10	0.70	1.06	Original	0.11	0.09	0.15	1.19	Imputed
rs11202596	89637134	A	0.09	0.08	0.58	1.09	Original	0.04	0.05	0.44	0.85	Imputed
rs1234219	89639557	G	0.08	0.07	0.47	1.13	Imputed	0.07	0.06	0.26	1.20	Imputed
rs7069904	89639818	A	0.03	0.02	0.41	1.27	Imputed	0.01	0.00	0.21	1.91	Imputed
rs1234218	89640739	T	0.07	0.07	0.69	1.07	Imputed	0.07	0.06	0.30	1.17	Imputed
rs1903858	89643666	G	0.32	0.30	0.26	1.11	Imputed	0.27	0.28	0.66	0.96	Imputed
rs2299939	89647130	A	0.19	0.20	0.49	0.93	Original	0.08	0.09	0.19	0.80	Imputed
rs1234225	89663549	T	0.36	0.33	0.10	1.16	Imputed	0.33	0.33	0.72	1.03	Imputed
rs12569998	89664137	G	0.14	0.14	0.95	0.99	Imputed	0.13	0.13	0.56	0.94	Original
rs1234224	89665276	G	0.36	0.33	0.10	1.16	Imputed	0.33	0.33	0.72	1.03	Imputed
rs1234223	89665570	C	0.10	0.10	0.68	1.06	Imputed	0.11	0.09	0.15	1.19	Imputed
rs17106896	89667087	T	0.05	0.04	0.19	1.30	Imputed	0.01	0.01	0.32	1.58	Imputed
rs1676759	89668276	G	0.03	0.03	0.98	1.01	Imputed	0.01	0.01	0.96	1.02	Imputed
rs11202600	89672813	C	0.07	0.07	0.69	1.07	Imputed	0.09	0.07	0.06	1.29	Original
rs10490920	89675623	C	0.14	0.14	0.95	0.99	Imputed	0.12	0.13	0.48	0.93	Imputed
rs1234213	89679301	A	0.36	0.33	0.09	1.16	Imputed	0.33	0.33	0.75	1.03	Imputed
rs7078674	89687333	O	0.00	0.00	NA	NA	Imputed	0.00	0.00	NA	NA	Imputed
rs12357281	89690651	C	0.09	0.08	0.64	1.07	Imputed	0.04	0.05	0.38	0.84	Imputed
rs2299941	89694699	G	0.14	0.14	0.98	1.00	Imputed	0.12	0.13	0.41	0.91	Imputed
rs2735343	89695409	C	0.36	0.33	0.11	1.15	Imputed	0.33	0.33	0.79	1.02	Imputed
rs2248293	89697245	C	0.36	0.33	0.11	1.15	Original	0.30	0.30	0.75	0.97	Imputed
rs17562384	89699396	C	0.19	0.20	0.47	0.93	Imputed	0.08	0.09	0.17	0.79	Imputed
rs2673832	89702453	G	0.11	0.10	0.44	1.11	Original	0.02	0.02	0.38	0.76	Imputed
rs12572106	89706087	C	0.14	0.14	0.98	1.00	Imputed	0.12	0.13	0.48	0.93	Imputed
rs17431184	89710231	C	0.19	0.20	0.47	0.93	Imputed	0.08	0.10	0.15	0.78	Imputed
rs2736627	89711074	C	0.09	0.09	0.64	1.07	Imputed	0.02	0.02	0.38	0.76	Imputed
rs926091	89711392	T	0.14	0.14	0.98	1.00	Imputed	0.12	0.13	0.48	0.93	Imputed
rs532678	89713322	T	0.36	0.33	0.11	1.15	Imputed	0.33	0.33	0.80	1.02	Imputed
rs11202607	89717394	T	0.07	0.07	0.67	1.07	Original	0.07	0.06	0.31	1.17	Imputed
rs478839	89721850	G	0.39	0.42	0.25	0.91	Original	0.38	0.38	0.92	0.99	Imputed
rs17346680	89727081	A	0.04	0.04	0.98	1.00	Imputed	0.07	0.06	0.20	1.22	Original
rs10509532	89727534	T	0.14	0.14	0.91	0.99	Original	0.12	0.13	0.48	0.93	Original

Abbreviations: CGEMS, cancer genetic markers of susceptibility; GWAS, whole genome-wide association study; OR, odds ratio; SNPs, single nucleotide polymorphisms.

^aP and OR are calculated based on an unconditional logistic regression with adjustment for age and geographic region, assuming an additive model of inheritance. [▲]F_A, frequency in aggressive cases; F_U, frequency in non-aggressive cases.

This is the first time that germ-line variants of *PTEN*, including both rare and common variants and CNVs, were comprehensively evaluated in hereditary and sporadic PCa populations. The *PTEN* region was re-sequenced in a large sample size ($n=188$) of HPC probands. No deleterious variants were found to contribute to PCa susceptibility, which was consistent with previous studies.^{13,14} Co-segregation of 10 rare variants, which were believed to give rise to high-penetrant HPC, was further evaluated by testing two micro-satellite markers flanking *PTEN* in the HPC families. However, co-segregation was not observed in the HPC families. Common variants, which were believed to contribute low-penetrant PCa, were explored in sporadic PCa populations and no association was found between the SNPs and PCa risk, consistent with previous studies.^{15,16} It was also the first time that germ-line CNVs in *PTEN* were explored for PCa susceptibility. In our study, there were no CNV probes on *PTEN* region, and three SNP probes were used to define CNVs for *PTEN*. No CNV defined by the three SNPs at *PTEN* was found to be associated with sporadic PCa. Based on the available CNV information from

Hapmap,²⁶ the nearest CNVs on the 5' and 3' flank region of *PTEN* (89 613 715–89 718 382) are 87 791 026–87 798 355 (~1.8 Mbp on 5' region) and 90 932 947–90 938 070 (~1.2 Mbp on 3' region), respectively. It is possible that CNVs at *PTEN* can be detected by microarrays with higher resolution.

To date, there have not been any germ-line variants in *PTEN* found to contribute to PCa susceptibility. However, the possibility can not be eliminated that germ-line and/or somatic sequence variants in *PTEN* may be associated with PCa aggressiveness. In the literature the presence of TMPRSS2: ERG fusion and a *PTEN* deletion was reported to be associated with a more aggressive form of PCa.²⁷ In our studies, however, germ-line sequence variants of *PTEN* did not serve as indicator for the aggressiveness of PCa from the GWAS studies in both CGEM and GASP2 population. Therefore, germ-line sequence variants of *PTEN* could not serve as an indicator for the aggressiveness of PCa.

In conclusion, this study suggests that *PTEN* germ-line SNPs are unlikely to have an important role in hereditary and non-hereditary PCa susceptibility.

- 1 Di Cristofano, A. & Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. *Cell* **100**, 387–390 (2000).
- 2 Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. PTEN is essential for embryonic development and tumor suppression. *Nature Genet.* **19**, 348–355 (1998).
- 3 Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J. *et al.* Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* **4**, 209–221 (2003).
- 4 Abate-Shen, C., Banach-Petrosky, W. A., Sun, X., Economides, K. D., Desai, N., Gregg, J. P. *et al.* Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. *Cancer Res.* **63**, 3886–3890 (2003).
- 5 Halvorsen, O., Haukaas, S. A. & Akslen, L. A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by ki-67 and increased risk of recurrent disease in localized prostate cancer. *Clin. Cancer Res.* **9**, 1474–1479 (2003).
- 6 Dong, J. T., Li, C. L., Sipe, T. W. & Frierson, H. F. Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. *Clin. Cancer Res.* **7**, 304–308 (2001).
- 7 Simpson, L. & Parsons, R. PTEN: life as a tumor suppressor. *Exp. Cell Res.* **264**, 29–41 (2001).
- 8 Schmitz, M., Grignard, G., Margue, C., Dippel, W., Capesius, C., Mossong, J. *et al.* Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. *Int. J. Cancer* **120**, 1284–1292 (2006).
- 9 Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S. *et al.* Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* **436**, 117–122 (2005).
- 10 Verhagen, P. C., Duijijn, P. W., Hermans, K. G., Looijenga, L. H., Van Gurp, R. J., Stoop, H. *et al.* The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. *J. Pathol.* **208**, 699–707 (2006).
- 11 Witte, J. S., Goddard, K. A., Conti, D. V., Elston, R. C., Lin, J., Suarez, B. K. *et al.* Genomewide scan for prostate cancer-aggressiveness loci. *Am. J. Hum. Genet.* **67**, 92–99 (2000).
- 12 Gibbs, M., Stanford, J. L., Jarvik, G. P., Janer, M., Badzioch, M., Peters, M. A. *et al.* A genomic scan of families with prostate cancer identifies multiple regions of interest. *Am. J. Hum. Genet.* **67**, 100–109 (2000).
- 13 Cooney, K. A., Tsou, H. C., Petty, E. M., Miesfeldt, S., Ping, X. L., Gruener, A. C. *et al.* Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. *Clin. Cancer Res.* **5**, 1387–1391 (1999).
- 14 Forrest, M. S., Edwards, S. M., Hamoudi, R. A., Dearnaley, D. P., Arden-Jones, A., Dowe, A. *et al.* No evidence of germline PTEN mutations in familial prostate cancer. *J. Med. Genet.* **3**, 210–212 (2000).
- 15 Bar-Shira, A., Matarasso, N., Rosner, S., Bercovich, D., Matzkin, H. & Orr-Urtreger, A. Mutation screening and association study of the Candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6. *Prostate* **66**, 1052–1060 (2006).
- 16 Haiman, C. A., Stram, D. O., Cheng, I., Giorgi, E. E., Pooler, L., Penney, K. *et al.* Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. *Cancer Epidemiol. Biomarkers. Prev.* **15**, 1021–1025 (2006).
- 17 Xu, J., Gillanders, E. M., Isaacs, S. D., Chang, B. L., Wiley, K. E., Zheng, S. L. *et al.* Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. *Prostate* **57**, 320–325 (2003).
- 18 Zheng, S. L., Sun, J., Wiklund, F., Smith, S., Stattin, P., Li, G. *et al.* Cumulative association of five genetic variants with prostate cancer. *N. Engl. J. Med.* **358**, 910–919 (2008).
- 19 Yeager, M., Orr, N., Hayes, R. B., Jacobs, K. B., Kraft, P., Wacholder, S. *et al.* Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat. Genet.* **39**, 645–649 (2007).
- 20 Thomas, G., Jacobs, K. B., Yeager, M., Kraft, P., Wacholder, S., Orr, N. *et al.* Multiple loci identified in a genome-wide association study of prostate cancer. *Nat. Genet.* **40**, 310–315 (2008).
- 21 Amundadottir, L. T., Sulem, P., Gudmundsson, J., Helgason, A., Baker, A., Agnarsson, B. A. *et al.* A common variant associated with prostate cancer in European and African populations. *Nat. Genet.* **38**, 652–658 (2006).
- 22 Duggan, D., Zheng, S. L., Knowlton, M., Benitez, D., Dimitrov, L., Wiklund, F. *et al.* Two genome wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. *J. Natl Cancer Inst.* **99**, 1836–1844 (2007).
- 23 Liu, W., Sun, J., Li, G., Zhu, Y., Zhang, S., Kim, S. T. *et al.* Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. *Cancer Res.* **69**, 2176–2179 (2009).
- 24 Laird, N. M., Horvath, S. & Xu, X. Implementing a unified approach to family-based tests of association. *Genet. Epidemiol.* **19**, S26–42 (2000).
- 25 Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**, 906–913 (2007).
- 26 McCarroll, S. A., Kuruvilla, F. G., Korn, J. M., Cawley, S., Nemesh, J., Wysoker, A. *et al.* Integrated detection and population-genetic analysis of SNPs and copy number variation. *Nat. Genet.* **40**, 1166–1174 (2008).
- 27 Yoshimoto, M., Joshua, A. M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Ludkovski, O. *et al.* Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. *Mod. Pathol.* **23**, 1–10 (2008).